Table 2 |
||||||
|
Gene Ontology Enrichment |
||||||
|
ENV |
NEF |
TAT |
||||
|
HHP |
HHE |
HHP |
HHE |
HHP |
HHE |
|
|
|
||||||
|
adenyl ribonucleotide binding |
9.9E-10 |
9.9E-10 |
4.8E-10 |
4.8E-10 |
7.8E-12 |
7.8E-12 |
|
inositol or phosphatidylinositol kinase activity |
6.6E-06 |
6.6E-06 |
1.6E-06 |
1.6E-06 |
7.7E-06 |
7.7E-06 |
|
interleukin receptor activity |
3.4E-07 |
3.4E-07 |
4.7E-08 |
4.7E-08 |
6.0E-08 |
6.0E-08 |
|
lipid kinase activity |
1.4E-04 |
1.4E-04 |
4.9E-05 |
4.9E-05 |
1.3E-05 |
1.3E-05 |
|
MAP kinase activity |
1.4E-04 |
1.4E-04 |
4.1E-05 |
4.1E-05 |
NA |
NA |
|
MAP kinase kinase kinase activity |
2.3E-03 |
2.3E-03 |
7.5E-04 |
7.5E-04 |
NA |
NA |
|
phosphoric monoester hydrolase activity |
4.9E-07 |
4.9E-07 |
1.9E-03 |
1.9E-03 |
NA |
NA |
|
protein kinase activity |
7.9E-32 |
7.9E-32 |
1.6E-28 |
1.6E-28 |
6.6E-33 |
6.6E-33 |
|
protein kinase binding |
1.1E-05 |
1.1E-05 |
1.7E-04 |
1.7E-04 |
2.0E-07 |
2.0E-07 |
|
|
||||||
|
GO molecular function level 5 categories statistically enriched (p-value < 0.01) by HHP for ENV, NEF, and TAT. HHE enrichment is also indicated. |
||||||
|
Evans et al. BMC Medical Genomics 2009 2:27 doi:10.1186/1755-8794-2-27 |
||||||